Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

1.

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.

Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM.

Clin Cancer Res. 2008 Feb 1;14(3):865-74. doi: 10.1158/1078-0432.CCR-07-1299.

PMID:
18245550
[PubMed - indexed for MEDLINE]
Free Article
2.

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.

Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.

Clin Cancer Res. 2006 Nov 15;12(22):6826-35.

PMID:
17121904
[PubMed - indexed for MEDLINE]
Free Article
3.

Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.

Schwock J, Pham NA, Cao MP, Hedley DW.

Cancer Chemother Pharmacol. 2008 Apr;61(4):669-81. Epub 2007 Jun 20.

PMID:
17579866
[PubMed - indexed for MEDLINE]
4.

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.

Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.

Br J Haematol. 2007 Feb;136(3):414-23. Epub 2006 Dec 14.

PMID:
17173546
[PubMed - indexed for MEDLINE]
5.

Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.

Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R.

Clin Cancer Res. 2004 Jul 15;10(14):4813-21.

PMID:
15269157
[PubMed - indexed for MEDLINE]
Free Article
6.

Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.

Robles AI, Wright MH, Gandhi B, Feis SS, Hanigan CL, Wiestner A, Varticovski L.

Clin Cancer Res. 2006 Nov 1;12(21):6547-56.

PMID:
17085670
[PubMed - indexed for MEDLINE]
Free Article
7.

Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.

Duus J, Bahar HI, Venkataraman G, Ozpuyan F, Izban KF, Al-Masri H, Maududi T, Toor A, Alkan S.

Leuk Lymphoma. 2006 Jul;47(7):1369-78.

PMID:
16923571
[PubMed - indexed for MEDLINE]
8.

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.

Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, Stoeltzing O.

Clin Cancer Res. 2007 Nov 1;13(21):6459-68.

PMID:
17975158
[PubMed - indexed for MEDLINE]
Free Article
9.

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.

Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC.

Br J Haematol. 2007 Sep;138(6):783-91.

PMID:
17760810
[PubMed - indexed for MEDLINE]
10.

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival.

Chatterjee M, Jain S, Stühmer T, Andrulis M, Ungethüm U, Kuban RJ, Lorentz H, Bommert K, Topp M, Krämer D, Müller-Hermelink HK, Einsele H, Greiner A, Bargou RC.

Blood. 2007 Jan 15;109(2):720-8. Epub 2006 Sep 26.

PMID:
17003370
[PubMed - indexed for MEDLINE]
Free Article
11.

Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.

David E, Sinha R, Chen J, Sun SY, Kaufman JL, Lonial S.

Clin Cancer Res. 2008 Aug 15;14(16):5090-8. doi: 10.1158/1078-0432.CCR-08-0016.

PMID:
18698026
[PubMed - indexed for MEDLINE]
Free Article
12.

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.

Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Nov;6(11):2868-78.

PMID:
18025273
[PubMed - indexed for MEDLINE]
Free Article
13.

Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.

Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.

J Exp Ther Oncol. 2008;7(3):183-93.

PMID:
19066127
[PubMed - indexed for MEDLINE]
14.

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC.

Blood. 2009 Jan 22;113(4):846-55. doi: 10.1182/blood-2008-04-151928. Epub 2008 Oct 23.

PMID:
18948577
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.

Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC.

Cancer Res. 2002 Sep 1;62(17):5019-26.

PMID:
12208756
[PubMed - indexed for MEDLINE]
Free Article
16.

Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN.

Cancer Biol Ther. 2009 Jul;8(13):1273-80.

PMID:
19440035
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.

Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.

Cancer Lett. 2009 Oct 18;284(1):62-70. doi: 10.1016/j.canlet.2009.04.012. Epub 2009 May 21.

PMID:
19464103
[PubMed - indexed for MEDLINE]
18.

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC.

Cancer Res. 2006 Jul 1;66(13):6675-82.

PMID:
16818641
[PubMed - indexed for MEDLINE]
Free Article
19.

Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.

Wong C, Chen S.

Cancer Res. 2009 Nov 15;69(22):8670-7. doi: 10.1158/0008-5472.CAN-09-1259. Epub 2009 Oct 27.

PMID:
19861537
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC.

Blood. 2007 Sep 1;110(5):1656-63. Epub 2007 May 17.

PMID:
17510321
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk